Valuation: AstraZeneca PLC

Market Cap 25TCr 22TCr 21TCr 19TCr 36TCr 23,76100Cr 36TCr 2,50000Cr 98TCr 12,39800Cr 94TCr 92TCr 39,67100Cr P/E 2026 *
21.1x
P/E 2027 * 18.2x
Enterprise Value 27TCr 24TCr 22TCr 20TCr 38TCr 25,65000Cr 39TCr 2,69900Cr 1,05600Cr 13,38300Cr 1,01600Cr 99TCr 42,82500Cr EV / Sales 2026 *
4.27x
EV / Sales 2027 * 3.91x
Free-Float
96.62%
Yield 2026 *
2.07%
Yield 2027 * 2.19%
1 day+3.35%
Current month+80.35%
Current year+82.00%
Current year 89.04
Extreme 89.04
169.81
1 year 80.48
Extreme 80.48
169.81
3 years 60.47
Extreme 60.47
169.81
5 years 52.65
Extreme 52.65
169.81
10 years 25.55
Extreme 25.55
169.81
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Chief Operating Officer 55 01/06/2015
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+3.28%+1.19% - - 25TCr
+4.94%+8.29%+53.23%+105.40% 1,07700Cr
-0.14%-1.05%+32.75%+61.10% 61TCr
+1.15%+4.92%+26.35%+94.14% 50TCr
-0.05%+3.72%+75.57%+41.80% 36TCr
+2.37%+7.66%+33.65%+50.58% 35TCr
+2.64%+6.95%+21.01%+44.38% 28TCr
+3.24%+6.78%+0.43%+15.73% 25TCr
+3.24%+8.01%+48.01%+53.40% 23TCr
+3.23%+8.10%+34.42%+100.78% 19TCr
Average +2.38%+1.97%+36.16%+63.04% 42.85TCr
Weighted average by Cap. +2.53%+1.58%+39.81%+72.33%

Financials

2026 *2027 *
Net sales 6.34TCr 5.66TCr 5.26TCr 4.78TCr 9TCr 6,00500Cr 9.16TCr 63TCr 25TCr 3,13300Cr 24TCr 23TCr 10,02600Cr 6.74TCr 6.01TCr 5.59TCr 5.08TCr 9.56TCr 6,38100Cr 9.74TCr 67TCr 26TCr 3,32900Cr 25TCr 25TCr 10,65300Cr
Net income 1.18TCr 1.05TCr 979.35Cr 890.84Cr 1.68TCr 1,11800Cr 1.71TCr 12TCr 4.6TCr 58TCr 4.43TCr 4.34TCr 1,86700Cr 1.37TCr 1.23TCr 1.14TCr 1.04TCr 1.95TCr 1,30000Cr 1.98TCr 14TCr 5.35TCr 68TCr 5.15TCr 5.04TCr 2,17100Cr
Net Debt 1.99TCr 1.78TCr 1.65TCr 1.5TCr 2.83TCr 1,88900Cr 2.88TCr 20TCr 7.77TCr 99TCr 7.48TCr 7.32TCr 3,15300Cr 1.23TCr 1.1TCr 1.02TCr 928.56Cr 1.75TCr 1,16500Cr 1.78TCr 12TCr 4.8TCr 61TCr 4.62TCr 4.52TCr 1,94600Cr
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
15/26/15 $167.27 +3.24% 30,69,823
14/26/14 $162.03 +3.99% 33,33,925
13/26/13 $155.82 -1.59% 31,12,422
12/26/12 $158.33 -0.55% 28,55,694
09/26/09 $159.20 +0.26% 21,21,775
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
161.75USD
Average target price
208.95USD
Spread / Average Target
+29.18%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC